Congratulations to our client Orasis Pharmaceuticals, on its entering into Licensing Agreement with Optus Pharmaceuticals for Commercialization of Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in Korea.
The transaction included $18 Million in Milestone Payments to Orasis, together with a Double-Digit Royalty on Sales in the Korean Market.
The team represented Orasis in this licensing agreement are the partners Shmulik Atias and Hili Cohen from Our International and Hi-Tech Department.
